Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427841 · ClinicalTrials.gov registry record · Phase 2
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02427841 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT02427841, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery. Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving nab-paclitaxel, gemcitabine hydrochloride, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Fluorouracil
- OTHER Laboratory Biomarker Analysis
- DRUG Gemcitabine
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION Image Guided Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01-21 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02427841
The ClinicalTrials.gov registry entry for NCT02427841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluorouracil is the first listed.
NCT02427841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02427841 about?
NCT02427841 is a clinical study titled "Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery. Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ...
What is the current status of trial NCT02427841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-01-21. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT02427841?
The interventions under investigation include: Fluorouracil (DRUG), Laboratory Biomarker Analysis (OTHER), Gemcitabine (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Image Guided Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02427841?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.